Hereditary Transthyretin Amyloidosis
Hereditary Transthyretin Amyloidosis Competitive and Market

Hereditary Transthyretin Amyloidosis (hATTR) is caused due to the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). The mutations in the gene for TTR frequently lead to the instability of TTR and subsequent fibril formation.


hATTR can be sub-classified into Familial Amyloid Polyneuropathy (FAP) And Familial Amyloid Cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in several tissues results in ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.


Hereditary Transthyretin Amyloidosis Epidemiological Segmentation 

The Epidemiological Segmentation of Hereditary Transthyretin Amyloidosis in 7MM from 2017 to 2030 is segmented as:- 

  • Diagnosed Prevalent Pool of Hereditary Transthyretin Amyloidosis (hATTR)
  • Type-Specific Prevalent Pool of Hereditary Transthyretin Amyloidosis (hATTR)


Hereditary Transthyretin Amyloidosis Epidemiology 

  • Hereditary Transthyretin Amyloidosis has the highest diagnosed prevalence in the United States with a 10.2% growth rate
  • Japan has the lowest diagnosed number that is growing at a CAGR of 9.9% over the forecast period
  • Familial Amyloid Polyneuropathy (FAP) patients in the United States were 2,588 in 2017 


Hereditary Transthyretin Amyloidosis Market

The Market Size of Hereditary Transthyretin Amyloidosis (hATTR) in 7MM in 2017 was USD 306.9 Million  


Hereditary Transthyretin Amyloidosis Market Drivers

  • Recent approvals of effective treatment
  • Diverse Pathophysiology
  • Increased awareness
  • Increasing healthcare expenditure and improved reimbursement policies

 

Hereditary Transthyretin Amyloidosis Market Barriers

  • Misdiagnosis
  • Diagnostic barriers
  • Lack of novel therapies in the pipeline


Hereditary Transthyretin Amyloidosis Emerging Drugs

The emerging drugs of the Hereditary Transthyretin Amyloidosis market are 

  • Vutrisiran
  • AKCEA-TTR-LRx
  • AG 10

And many others. 


Hereditary Transthyretin Amyloidosis Key Players

The key players in the Hereditary Transthyretin Amyloidosis market are

  • Alnylam Pharmaceuticals
  • IonisPharmaceuticals
  • Eidos Therapeutics

 And many others.